Delisting riskPopularity #4,858
Citius Oncology (CTOR)
Commercializing LYMPHIR for relapsed or refractory cutaneous T-cell lymphoma.
$1.05
vs last close−0.02 (−1.87%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 15.21% | 14.15M shares | |
|---|---|---|---|
| 20 holders · as of Jun 30, 2026 | |||
| Insiders | 6.58% | 6.12M shares | |
| 10 holders · as of Sep 23, 2025 | |||
| Other | 78.21% | 72.71M shares | |
| remainder | |||
92.98M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
20 holders · 14.15M shares · 8 new positions · 10 increased · 3 reduced · 1 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Armistice Capital, LLC | 8.71M | 9.36% | −483.3K | Aug 14, 2026 |
| Bank of America Corp /DE/ | 3.84M | 4.12% | 0 | Aug 14, 2026 |
| Vanguard Capital Management LLC | 546.3K | 0.59% | +11.5K | Aug 13, 2026 |
| UBS Group AG | 334.6K | 0.36% | +297.8K | Aug 13, 2026 |
| Geode Capital Management, LLC | 245.4K | 0.26% | −19.3K | Aug 12, 2026 |
| Vanguard Fiduciary Trust Co | 121.9K | 0.13% | 0 | Aug 13, 2026 |
| Ifp Advisors, Inc | 107.4K | 0.12% | 0 | Jul 20, 2026 |
| Citadel Advisors LLC | 90.6K | 0.10% | +90.6Knew | Sep 2, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Armistice Capital, LLC | 9.99% | 9.30M | 13G | May 15, 2026 |
Form 4
Latest trades
No open-market trades in the last 12 months.
House and Senate disclosures
Not reported.